Cardiff Oncology Inc (CRDF)

Apr 15, 2026

Cardiff Oncology (CRDF) price target decreased by 17.38% to 8.74 - MSN

Apr 15, 2026

Apr 12, 2026

Cardiff Oncology appoints Mani Mohindru as CEO - MSN

Apr 12, 2026

Apr 11, 2026

Momentum Shift: Is Cardiff Oncology Inc likely to announce a buyback2026 Breakouts & Breakdowns & Smart Swing Trading Techniques - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

Cardiff Oncology Appoints Mani Mohindru as CEO and Expands Executive Team to Advance Cancer Drug Onvansertib - Minichart

Apr 10, 2026

Apr 09, 2026

Cardiff Oncology announces key leadership appointments to strengthen executive team for next phase of growth - marketscreener.com

Apr 09, 2026

Apr 09, 2026

Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth - Bitget

Apr 09, 2026

Apr 09, 2026

Cardiff Oncology, Inc. Announces Management Appointments - marketscreener.com

Apr 09, 2026

Apr 09, 2026

Cardiff Oncology (CRDF) Appoints New Leadership Team - GuruFocus

Apr 09, 2026

Apr 09, 2026

Cardiff Oncology, Inc. Appoints Josh Muntner as Chief Financial Officer, Effective April 6, 2026 - marketscreener.com

Apr 09, 2026

Apr 09, 2026

Cardiff Oncology, Inc. Appoints Mani Mohindru as Chief Executive Officer - marketscreener.com

Apr 09, 2026

Apr 09, 2026

Cardiff Oncology appoints new CEO, CFO and COO - TipRanks

Apr 09, 2026

Apr 09, 2026

Form 8-KCurrent report - ADVFN

Apr 09, 2026

Apr 06, 2026

Cardiff Oncology: Market Dismisses Onvansertib's Potential In First-Line Colorectal Cancer - Seeking Alpha

Apr 06, 2026

Apr 06, 2026

Short Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Declines By 9.4% - 富途牛牛

Apr 06, 2026

Apr 04, 2026

CRDF Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026

Apr 02, 2026

Cardiff Oncology Formalizes Executive Departures Amid Strategic Review - TipRanks

Apr 02, 2026

Apr 02, 2026

Cardiff Oncology Inc. (CRDF) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Apr 02, 2026

Apr 02, 2026

Cardiff Oncology director Dr. Erlander resigns - TradingView — Track All Markets

Apr 02, 2026

Apr 02, 2026

Cardiff Oncology (CRDF) CEO awarded 600,000 options at $1.62 strike - Stock Titan

Apr 02, 2026

Apr 02, 2026

[8-K] Cardiff Oncology, Inc. Reports Material Event - Stock Titan

Apr 02, 2026

Apr 02, 2026

Cardiff Oncology, Inc. Announces Resignation of Mark Erlander as Director - marketscreener.com

Apr 02, 2026

Apr 01, 2026

CRDF SEC FilingsCardiff Oncology Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 01, 2026

Mar 31, 2026

Jobs Data: Can Cardiff Oncology Inc reach all time highs this yearTreasury Yields & Daily Momentum Trading Reports - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

Noble Financial Issues Optimistic Estimate for CRDF Earnings - MarketBeat

Mar 30, 2026

Mar 28, 2026

Growth Review: What is the PEG ratio of Cardiff Oncology Inc2026 Buyback Activity & Risk Controlled Daily Plans - baoquankhu1.vn

Mar 28, 2026

Mar 27, 2026

Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Mar 27, 2026

Mar 27, 2026

Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF) - The Globe and Mail

Mar 27, 2026

Mar 26, 2026

Vanguard (NASDAQ: CRDF) reports 0 shares after Jan 12, 2026 realignment - stocktitan.net

Mar 26, 2026

Mar 26, 2026

Craig-Hallum reiterates Buy on Cardiff Oncology stock, $10 target By Investing.com - Investing.com Canada

Mar 26, 2026

Mar 26, 2026

Craig-Hallum reiterates Buy on Cardiff Oncology stock, $10 target - Investing.com

Mar 26, 2026

Mar 26, 2026

William Blair reiterates Cardiff Oncology stock rating on drug data By Investing.com - ca.investing.com

Mar 26, 2026

Mar 26, 2026

H.C. Wainwright reiterates Cardiff Oncology stock rating at buy - Investing.com

Mar 26, 2026

Mar 26, 2026

H.C. Wainwright reiterates Cardiff Oncology stock rating at buy By Investing.com - Investing.com Canada

Mar 26, 2026

Mar 26, 2026

Cardiff Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

Mar 26, 2026

Mar 25, 2026

CRDF: Onvansertib plus FOLFIRI+BEV achieved a 72% response rate and strong PFS in RAS mutated CRC - TradingView

Mar 25, 2026

Mar 25, 2026

Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar - MarketBeat

Mar 25, 2026

Mar 25, 2026

Cardiff Oncology Inc to Host KOL Webinar Transcript - gurufocus.com

Mar 25, 2026

Mar 25, 2026

Published on: 2026-03-26 02:49:36 - baoquankhu1.vn

Mar 25, 2026

Mar 20, 2026

Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer - 富途牛牛

Mar 20, 2026

Mar 20, 2026

Cardiff Oncology to Host Key Opinion Leader Discussion - GlobeNewswire

Mar 20, 2026

Mar 19, 2026

Cardiff Oncology to present preclinical data at cancer conference By Investing.com - Investing.com Canada

Mar 19, 2026

Mar 19, 2026

Cardiff Oncology to present preclinical data at cancer conference - Investing.com

Mar 19, 2026

Mar 19, 2026

Cardiff Oncology Presents Promising Preclinical Data on Onvansertib at AACR Annual Meeting 2026 - Quiver Quantitative

Mar 19, 2026

Mar 19, 2026

Cardiff Oncology to Present Preclinical Data with Highly - GlobeNewswire

Mar 19, 2026

Mar 18, 2026

Levels Update: Can Cardiff Oncology Inc reach all time highs this year - baoquankhu1.vn

Mar 18, 2026

Mar 18, 2026

Ladenburg Thalmann Initiates Coverage of Cardiff Oncology (CRDF) with Buy Recommendation - MSN

Mar 18, 2026

Mar 18, 2026

IPO Launch: Whats the analyst consensus on Cardiff Oncology IncWeekly Trade Review & High Conviction Trade Alerts - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

Jobs Data: Is Cardiff Oncology Inc undervalued by DCF analysisWeekly Investment Recap & Fast Moving Stock Trade Plans - baoquankhu1.vn

Mar 17, 2026

Mar 12, 2026

Rate Cut: Can Cardiff Oncology Inc reach all time highs this yearPortfolio Performance Summary & Free Community Supported Trade Ideas - baoquankhu1.vn

Mar 12, 2026

Mar 11, 2026

Cardiff Oncology (STU:XE7C) NonCurrent Deferred Revenue : €0.00 Mil (As of Dec. 2025) - GuruFocus

Mar 11, 2026